S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Stock Price, News & Analysis (NYSE:ZOM)

$0.34
+0.01 (+3.02 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$0.32
Now: $0.34
$0.35
50-Day Range
$0.32
MA: $0.38
$0.46
52-Week Range
$0.20
Now: $0.34
$1.85
Volume12,227 shs
Average Volume219,518 shs
Market Capitalization$36.83 million
P/E RatioN/A
Dividend YieldN/A
Beta0.24
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone734-369-2555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.04 per share

Profitability

Net Income$-16,650,000.00
Return on Equity-23,993.13%

Miscellaneous

EmployeesN/A
Market Cap$36.83 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.


Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."

How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) posted its earnings results on Thursday, August, 8th. The company reported ($0.02) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.04. View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s Earnings History.

When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

What is the consensus analysts' recommendation for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage?

News articles about ZOM stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a news impact score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors?

What other stocks do shareholders of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) own?

Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the folowing people:
  • Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
  • Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
  • Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
  • Mr. Bruk Herbst, Chief Commercial Officer (Age 49)

How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?

One share of ZOM stock can currently be purchased for approximately $0.34.

How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a market capitalization of $36.83 million. The company earns $-16,650,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. View Additional Information About Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website?

The official website for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is http://www.zomedica.com/.

How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected]


MarketBeat Community Rating for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE ZOM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel